logo

For the Inventor, By the Inventor

Bridgewater, NJ, United States of America

Insmed Incorporated


USPTO Granted Patents = 67

% Expired Patents = 11.9



Forward Citations = 982

Loading Chart...
Loading Chart...

51 inventors (with patents filed for the assignee):

goldMedal Vladimir Malinin (21 out of 23 patents)

silverMedal Renu Gupta (20 out of 20 patents)

bronzeMedal Gina Eagle (14 out of 16 patents)

4.  Adam Plaunt (14 out of 14 patents)

5.  Walter Perkins (14 out of 14 patents)

6.  Jeff Weers (11 out of 11 patents)

7.  Donna M Konicek (10 out of 10 patents)

8.  Franziska Leifer (8 out of 8 patents)

9.  Zhili Li (8 out of 9 patents)

10.  Brian S Miller (4 out of 7 patents)

11.  Lawrence T Boni (3 out of 17 patents)

12.  Xingong Li (3 out of 5 patents)

13.  Mark C Sleevi (3 out of 6 patents)

14.  Ju Du (3 out of 3 patents)

15.  Robert Worsham (3 out of 3 patents)


Core Competencies:
Pulmonary Disorders
Aminoglycosides
Treprostinil Prodrugs
DPP1 Inhibitors
Prostacyclin Compounds
Liposomal Formulations
Antibodies
Antiinfectives
Vancomycin Formulations
Lipid-Based Compositions
Cancer Treatments
D-Chiro-Inositol

67 patents:

1. 12679815 - Linear dipeptidyl peptidase 1 inhibitors and uses thereof (2026-07-14),
2. 12616708 - Methods for treating pulmonary non-tuberculous mycobacterial infections (2026-05-05),
3. 12521345 - Large-scale manufacturing methods for aminoglycosides (2026-01-13),
4. 12479837 - Reversible DPP1 inhibitors and uses thereof (2025-11-25),
5. 12377114 - Methods for treating pulmonary non-tuberculous mycobacterial infections (2025-08-05),
6. 12290600 - Methods for continuous manufacture of liposomal drug products (2025-05-06),
7. 12201725 - Dry powder compositions of treprostinil prodrugs and methods of use thereof (2025-01-21),
8. 12168022 - Methods for treating pulmonary non-tuberculous mycobacterial infections (2024-12-17),
9. 12168021 - Methods for treating pulmonary non-tuberculous mycobacterial infections (2024-12-17),
10. 12104186 - Deimmunized lysostaphin and methods of use (2024-10-01),
11. 12016873 - Methods for treating pulmonary non-tuberculous mycobacterial infections (2024-06-25),
12. 11998553 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis (2024-06-04),
13. 11857597 - Lipo-glycopeptide cleavable derivatives and uses thereof (2024-01-02),
14. 11795135 - Prostacyclin compounds, compositions and methods of use thereof (2023-10-24),
15. 11759425 - Dry powder compositions of treprostinil prodrugs and methods of use thereof (2023-09-19),
Insmed Incorporated is a biopharmaceutical company based in Bridgewater, New Jersey, specializing in innovative therapies for pulmonary infections and related disorders. The company focuses on developing advanced treatments utilizing core technologies such as aminoglycosides, treprostinil prodrugs, and DPP1 inhibitors. Insmed's research encompasses a range of therapeutic modalities, including liposomal formulations and anti-infectives, aimed at addressing unmet medical needs in the field of pulmonary health.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Insmed Incorporated
67 Patents

#5 in Bridgewater, NJ

#233 in New Jersey

#5,451 in US

#11,018 in the World

Bridgewater, NJ (US)
Bridgewater, NJ, United States of America

Insmed Incorporated

Forward Citations = 982

51 inventors:

goldMedal Vladimir Malinin (21 out of 23 patents)

silverMedal Renu Gupta (20 out of 20 patents)

bronzeMedal Gina Eagle (14 out of 16 patents)

4.  Adam Plaunt (14 out of 14 patents)

5.  Walter Perkins (14 out of 14 patents)

Please report any incorrect information to [email protected]
Loading…